With operations in South San Francisco, CA and Research Triangle Park, NC, Satsuma Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing STS101 (dihydroergotamine mesylate (DHE) nasal powder) as an important and differentiated therapeutic option for the acute treatment of migraine. Source
No articles found.
Oncolytics is focused on obtaining regulatory approval for pelareorep for metastat...
Oncolytics is focused on obtaining regulatory a...
We are a biopharmaceutical company focused on discovering, acquiring, developing a...
We are a biopharmaceutical company focused on d...
Progenics develops innovative medicines and other technologies to target and treat...
Progenics develops innovative medicines and oth...
BioSpecifics Technologies Corp. is a biopharmaceutical company that is the origina...
BioSpecifics Technologies Corp. is a biopharmac...
Join the National Investor Network and get the latest information with your interests in mind.